Xeris Biopharma Holdings, Inc. reported record total revenue of $60.119 million for the first quarter ended March 31, 2025, representing a 47.9% increase year-over-year. Product revenue grew by 43.6% year-over-year to $57.802 million, driven by strong demand across its portfolio. Recorlev revenue surged by 140.9% year-over-year to $25.530 million, and Gvoke revenue increased by 25.7% to $20.845 million.
The company achieved positive adjusted EBITDA of $4.4 million for the quarter, an improvement of $8.4 million compared to the first quarter of 2024, demonstrating enhanced operational efficiency. Net loss for the quarter improved to $9.2 million, or ($0.06) per share, compared to $18.98 million, or ($0.14) per share, in the prior year.
Based on its strong performance, Xeris tightened its full-year 2025 total revenue guidance to a range of $260 million to $275 million, from the previous range of $255 million to $275 million. This revision reflects confidence in the sustained momentum of its strategic initiatives and commercial execution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.